Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


08.07.2019

3 Arch Virol
1 Clin Infect Dis
2 Eur J Gastroenterol Hepatol
1 Hepatology
1 J Hepatol
1 J Infect Dis
1 J Interferon Cytokine Res
3 J Med Virol
2 J Viral Hepat
1 Lancet
1 MMWR Morb Mortal Wkly Rep
2 PLoS One
1 PLoS Pathog
1 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arch Virol

  1. DOGADOV DI, Korzaya LI, Kyuregyan KK, Karlsen AA, et al
    Natural infection of captive cynomolgus monkeys (Macaca fascicularis) with hepatitis E virus genotype 4.
    Arch Virol. 2019 Jul 3. pii: 10.1007/s00705-019-04337.
    PubMed     Text format     Abstract available

  2. LIMERES MJ, Gomez ER, Noseda DG, Cerrudo CS, et al
    Impact of hepatitis B virus genotype F on in vitro diagnosis: detection efficiency of HBsAg from Amerindian subgenotypes F1b and F4.
    Arch Virol. 2019 Jul 2. pii: 10.1007/s00705-019-04332.
    PubMed     Text format     Abstract available

  3. HUSSEINI AA, Saeed KMI, Yurdcu E, Sertoz R, et al
    Epidemiology of blood-borne viral infections in Afghanistan.
    Arch Virol. 2019;164:2083-2090.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  4. COOPER C
    Eliminating Hepatitis C (and the Unknowns) in the HIV Co-Infected.
    Clin Infect Dis. 2019 Jul 2. pii: 5527234. doi: 10.1093.
    PubMed     Text format    


    Eur J Gastroenterol Hepatol

  5. SARWAR S, Tarique S, Aleem A, Khan AA, et al
    Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Eur J Gastroenterol Hepatol. 2019;31:1035-1039.
    PubMed     Text format     Abstract available

  6. HWAN YJ, Shin J, Jin YJ, Lee JW, et al
    Comparison of clinical manifestations and outcomes of noncirrhotic and cirrhotic hepatocellular carcinoma patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Jul 1. doi: 10.1097/MEG.0000000000001478.
    PubMed     Text format     Abstract available


    Hepatology

  7. JONAS MM, Squires RH, Rhee SM, Lin CW, et al
    Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study.
    Hepatology. 2019 Jun 29. doi: 10.1002/hep.30840.
    PubMed     Text format     Abstract available


    J Hepatol

  8. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


    J Infect Dis

  9. SU TH, Yang HC, Tseng TC, Liou JM, et al
    Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy.
    J Infect Dis. 2018 Jan 2. pii: 4782512. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Interferon Cytokine Res

  10. PEDERGNANA V, Irving WL, Barnes E, McLauchlan J, et al
    Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
    J Interferon Cytokine Res. 2019 Jul 1. doi: 10.1089/jir.2019.0013.
    PubMed     Text format     Abstract available


    J Med Virol

  11. MARTINEZ AP, Garcia G, Ridruejo E, Culasso AC, et al
    Hepatitis C Virus Genotype 1 Infection: Prevalence of NS5A and NS5B Resistance-Associated Substitutions in Naive Patients from Argentina.
    J Med Virol. 2019 Jul 5. doi: 10.1002/jmv.25536.
    PubMed     Text format     Abstract available

  12. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25533.
    PubMed     Text format     Abstract available

  13. HUANG J, Xu R, Wang M, Liao Q, et al
    Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25531.
    PubMed     Text format     Abstract available


    J Viral Hepat

  14. MENDIZABAL M, Ridruejo E, Ceballos S, Sixto M, et al
    The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13172.
    PubMed     Text format     Abstract available

  15. PRONIER C, Fontaine H, Dorival C, Carrat F, et al
    Genetic diversity of genotype 6 HCV infections in France: epidemiology and consequences for treatment strategy.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13171.
    PubMed     Text format     Abstract available


    Lancet

  16. MAKONI M
    New scorecard reveals Africa's hepatitis cost.
    Lancet. 2019;393:2577.
    PubMed     Text format    


    MMWR Morb Mortal Wkly Rep


  17. Hepatitis Awareness Month and Testing Day - May 2019.
    MMWR Morb Mortal Wkly Rep. 2019;68:413.
    PubMed     Text format     Abstract available


    PLoS One

  18. OBIRI-YEBOAH D, Awuku YA, Adjei G, Cudjoe O, et al
    Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana.
    PLoS One. 2019;14:e0219148.
    PubMed     Text format     Abstract available

  19. RAIHAN R, Akbar SMF, Al Mahtab M, Takahashi K, et al
    Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.
    PLoS One. 2019;14:e0218744.
    PubMed     Text format     Abstract available


    PLoS Pathog

  20. HYUN J, McMahon RS, Lang AL, Edwards JS, et al
    HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells.
    PLoS Pathog. 2019;15:e1007883.
    PubMed     Text format     Abstract available


    Vaccine

  21. YU XY, Chen ZP, Wang SY, Pan HR, et al
    Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65years.
    Vaccine. 2019 Jun 28. pii: S0264-410X(19)30444.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: